Related references
Note: Only part of the references are listed.Sorafenib-induced premalignant and malignant skin lesions
Victoria L. Williams et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2011)
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
Lokesh Jain et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
Bruno Vincenzi et al.
ONCOLOGIST (2010)
Chemotherapeutic agents and the skin: An update
Noushin Heidary et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Do Patients Die from Rashes from Epidermal Growth Factor Receptor Inhibitors? A Systematic Review to Help Counsel Patients About Holding Therapy
Aminah Jatoi et al.
ONCOLOGIST (2008)
Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
A. F. S. Galimont-Collen et al.
EUROPEAN JOURNAL OF CANCER (2007)
Share Paper
